Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: Implication in the pathogenesis of Alzheimer's disease

Vascular Health and Risk Management

Volumn 4, Issue 3, 2008, Pages 721-730

  Aliev, Gjumrakch ^a   Gasimov, Eldar ^b   Obrenovich, Mark E ^c   Fischbach, Kathryn ^a   Shenk, Justin C ^a   Smith, Mark A ^c   Perry, George ^c,d  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

^b AZERBAIJAN MEDICAL UNIVERSITY   (Azerbaijan)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

^d University of San Antonio   (United States)

Author keywords

Alzheimer's disease; Atherosclerosis; Brain hypoperfusion; Electron microscopy; Transgenic animals; Vascular and mitochondrial lesions

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID PRECURSOR PROTEIN; CYTOCHROME C OXIDASE; MITOCHONDRIAL DNA;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ATHEROSCLEROSIS; BRAIN BIOPSY; BRAIN MICROCIRCULATION; BRAIN MITOCHONDRION; CONTROLLED STUDY; CORRELATION FUNCTION; DISEASE COURSE; GENE DELETION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IN SITU HYBRIDIZATION; MOUSE; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; TRANSGENIC MOUSE; YEAST ARTIFICIAL CHROMOSOME;

ALZHEIMER DISEASE; ANIMALS; ATHEROSCLEROSIS; BRAIN; DISEASE MODELS, ANIMAL; DNA, MITOCHONDRIAL; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROCIRCULATION; NEURONS;

EID: 47849127831     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Aliev G. 2002. Is non-genetic Alzheimer's disease a vascular disorder with neurodegenerative consequences? J Alzheimer's Dis, 4:513-16.
2. Aliev G, Liu J, Xu K, et al. 2007. ApoE4 in mice induces age-dependent brain hypoperfusion, neuronal, glial and microvascular damage, and cognitive impairment, which can be prevented by feeding Acetyl-L-Carnitine and R-Lipoic Acid. In: 8th International Conference on Alzheimer's and Parkinson's Diseases AD/PD (Salzburg, Austria). Proceeding AD/PD Conference 2007. Monduzzi Editore, Bologna, Italy. 2007 in press.
3. Aliev G, Obrenovich ME, Seyidova D, et al. 2005. Exploring ischemia-induced vascular lesions and potential pharmacological intervention strategies. Histol Histopathol, 20:261-73.
4. Aliev G, Seyidova D, Lamb BT, et al. 2003a. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res, 25:665-74.
5. Aliev G, Seyidova D, Neal ML, et al. 2002a. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels as a central target for the development of human AD and AD-like pathology in aged transgenic mice. Ann N Y Acad Sci, 977:45-64.
6. Aliev G, Shi J, Perry G, et al. 2000. Neuronal mitochondrial abnormalities in yeast artificial chromosome (YAC) transgenic mice overexpressing amyloid precursor protein (APP). Society for Neuroscience Abstracts Book, 30.
7. Aliev G, Smith MA, Obrenovich ME, et al. 2003b. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease. Neurotox Res, 5:491-504.
8. Aliev G, Smith MA, Seyidov D, et al. 2002b. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol, 12:21-35.
9. Aliev G, Smith MA, Vinters H, et al. 1999. Mitochondria abnormalities mark vulnerable neurons in Alzheimer's disease. J Neuropathol Exp. Neurol, 58:511.
10. Aliyev A, Chen SG, Seyidova D, et al. 2005. Mitochondria DNA deletions in atherosclerotic hypoperfused brain microvessels as a primary target for the development of Alzheimer's disease. J Neurol Sci, 229-230:285-92.
11. Aliyev A, Seyidova D, Rzayev N, et al. 2004. Is nitric oxide a key target in the pathogenesis of brain lesions during the development of Alzheimer's disease? Neurol Res, 26:547-53.
12. Annaházi A, Mracskó E, Süle Z, et al. 2007. Pre-treatment and post-treatment with alpha-tocopherol attenuates hippocampal neuronal damage in experimental cerebral hypoperfusion. Eur J Pharmacol, 571(2-3):120-8.
13. Cash AD, Aliev G, Siedlak SL, et al. 2003. Microtubule reduction in Alzheimer's disease and aging is independent of tau filament formation. Am J Pathol, 162:1623-7.
14. Choi SA, Kim EH, Lee JY, et al. 2007. Preconditioning with chronic cerebral hypoperfusion reduces a focal cerebral ischemic injury and increases apurinic/apyrimidinic endonuc-lease/redox factor-1 and matrix metalloproteinase-2 expression. Curr Neurovasc Res, 4:89-97.
15. De Jong GI, De Vos RA, Steur EN, et al. 1997. Cerebrovascular hypoperfusion: a risk factor for Alzheimer's disease? Animal model and postmortem human studies. Ann N Y Acad Sci, 826:56-74.
16. de la Torre JC. 1997. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann N Y Acad Sci, 826:75-91.
17. de la Torre JC. 2000. Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer's pathogenesis. Neurobiol Aging, 21:331-42.
18. de la Torre JC. 2002a. Alzheimer's disease: how does it start? J Alzheimer's Dis, 4:497-512.
19. de la Torre JC. 2002b. Alzheimer disease as a vascular disorder: nosological evidence. Stroke, 33:1152-62.
20. de la Torre JC. 2006. How do heart disease and stroke become risk factors for Alzheimer's disease? Neurol Res, 6:637-44.
21. de la Torre JC, Aliev G. 2005. Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes. J Cereb Blood Flow Metab, 25:663-72.
22. Friston KJ, Frackowiak RS. 1991. Cerebral function in aging and Alzheimer's disease: the role of PET. Electroencephalogr Clin Neurophysiol Suppl, 42:355-65.
23. Hirai K, Aliev G, Nunomura A, et al. 2001. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci, 21:3017-23.
24. Lamb BA, Bardel KA, Kulnane LS, et al. 1999. Amyloid production and deposition in mutant amyloid precursor protein and presenilin-1 yeast artificial chromosome transgenic mice. Nat Neurosci, 2:695-7.
25. Kumar A, Schapiro MB, Haxby JV, et al. 1990. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. J Psychiatr Res, 24:97-109.
26. Kalback W, Esh C, Castaño EM, et al. 2004. Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. Neurol Res, 26:525-39.
27. Lishmanov Y, Shvera I, Ussov W, et al. 1997. The effect of carotid endarterectomy on cerebral blood flow and cerebral blood volume studied by SPECT. J Neuroradiol, 24:155-62.
28. Moreira PI, Siedlak SL, Wang X, et al. 2007. Autophagocytosis of mitochondria is prominent in Alzheimer disease. J Neuropathol Exp Neurol, 66:525-32.
29. Nunomura A, Perry G, Aliev G, et al. 2001. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol, 60:759-67.
30. Roher AE, Esh C, Kokjohn TA, et al. 2003. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Arterioscler Thromb Vasc Biol, 23:2055-62.
31. Shi J, Perry G, Aliev G, et al. 1999. Serum amyloid P is not present in amyloid beta deposits of a transgenic animal model. Neuro Report, 10:3229-32.
32. Shi J, Perry G, Berridge MS, et al. 2002a. Labeling of cerebral amyloid beta deposits in vivo using intranasal basic fibroblast growth factor and serum amyloid P component in mice. J Nucl Med, 43:1044-51.
33. Shi J, Seyidova D, Perry G, et al. 2002b. Neuronal mitochondria abnormalities in a transgenic mouse model overexpressing amyloid beta. Society for Neuroscience 295.20.
34. Skoog I, Gustafson D. 2006. Update on hypertension and Alzheimer's disease. Neurol Res, 28:605-11.
35. Taguchi A, Matsuyama T, Moriwaki H, et al. 2004. Circulating CD34-positive cells provide an index of cerebrovascular function. Circulation, 109:2972-5.